Developmental Research Program (DRP)

发展研究计划（DRP）

• 批准号: 10263348
• 负责人: KATHRYN I POLLAK
• 金额: $ 9.87万
• 依托单位: DUKE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-14 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10263348
• 关键词: Advertisements; American Association of Cancer Research; Attention; Award; Basic Science; Cancer Science; Clinical; Clinical Research; Complement; Development; Diagnosis; Doctor of Philosophy; Ensure; Evaluation; Evolution; Faculty; Faculty Recruitment; Feedback; Funding; Funding Mechanisms; Future; Goals; Grant; Individual; Institutes; Institution; Intercept; Journals; Leadership; Malignant Neoplasms; Minority; Patient-Focused Outcomes; Peer Review; Pilot Projects; Population Research; Prevention; Probability; Process; Progress Reports; Research; Research Personnel; Research Project Grants; Review Committee; Source; Testing; Translational Research; United States National Institutes of Health; Universities; Woman; Work; cancer health disparity; experience; improved; improved outcome; medical schools; meetings; novel; novel strategies; programs; skills; translational cancer research; women faculty

ABSTRACT – Developmental Research Program The Developmental Research Program (DRP) is a critical component of the Duke Cancer Health Disparities (DCHD) P20 SPORE, supporting (1) pilot research projects with translational potential relevant to cancer disparities and (2) the participation of early stage and experienced investigators from other fields to work in translational cancer research. Projects are encouraged to test novel concepts and paradigms that bring new approaches into the field to further advance our understanding of cancer health disparities and to improve prevention, diagnosis, interception, and/or treatment. The DRP will specifically target projects that have a strong likelihood of developing into full projects for our planned DCHD P50 SPORE application or independent research projects (e.g. NIH R01 or similar funding mechanisms). Special attention will be given to promoting participation of women and minorities. The coordinated efforts of Co-Directors Gerard Blobe, MD, PhD, and Kathryn Pollak, PhD, with the DRP Scientific Review Committee (DRP-SRC), will ensure a proactive, productive DRP that prioritizes impactful pilot projects and faculty recruitment, and is well integrated into the overall P20 SPORE. The DRP will identify and support meritorious basic, translational, population, or clinical research projects that have a high probability of impacting cancer disparities at the level of prevention, diagnosis, interception, or treatment (Aim 1); attract outstanding new and/or experienced investigators, currently not working on cancer disparities, to pursue cancer disparities research (Aim 2); facilitate collaborative translational research to test novel concepts and paradigms relevant to cancer disparities in prevention, diagnosis, interception, or treatment (Aim 3); and evaluate progress on funded projects and facilitate their evolution into full SPORE projects or into independently funded projects (Aim 4). To accomplish these Aims, the DRP will award $100,000 each year to fund at least one promising project per year. Awardees will be eligible for renewed funding for one additional year, if satisfactory progress is made and an acceptable proposal and plan for the second year are presented. Strategies to solicit DRP applications will include direct solicitation to all faculty in the Duke Cancer Institute, Duke School of Medicine, and Duke University. In addition, cancer disparities research programs at other institutions nationwide will be contacted, and advertisements will be placed in appropriate clinical and scientific journals to attract collaborative applications from outside of Duke. All DRP applications will undergo a transparent multi-tiered peer review process. DRP awardees will be required to present progress reports on their projects on a rotating basis at the bi-weekly Executive Committee meetings, where they will receive feedback. The DRP and its processes will be evaluated annually as part of the DCHD P20 SPORE evaluation, and improvements instituted for the next cycle of solicitation, review, and award.

抽象-发展研究方案 发展研究计划(DRP)是杜克大学癌症健康差异的关键组成部分 (DCHD)P20孢子，支持(1)与癌症相关的具有翻译潜力的先导研究项目 差距和(2)来自其他领域的早期和有经验的调查人员的参与 转化性癌症研究。鼓励项目测试新的概念和范例，以带来新的 进一步加深我们对癌症健康差异的了解并改善 预防、诊断、拦截和/或治疗。DRP将专门针对那些具有较强 为我们计划的DCHD P50孢子应用或独立研究开发完整项目的可能性 项目(例如，NIH R01或类似的资助机制)。将特别注意促进参与 妇女和少数族裔。联席主任杰拉德·布洛布、医学博士、博士和凯瑟琳·波拉克的协调努力， 博士，与DRP科学审查委员会(DRP-SRC)一起，将确保一个积极、富有成效的DRP 优先考虑有影响力的试点项目和教师招聘，并很好地融入整个P20孢子。这个 DRP将确定并支持有价值的基础、翻译、人口或临床研究项目 在预防、诊断、拦截或治疗水平上影响癌症差异的高概率 (目标1)；吸引优秀的新的和/或有经验的调查人员，目前没有研究癌症差异， 开展癌症差异研究(目标2)；促进协作翻译研究以测试新概念 以及与癌症在预防、诊断、拦截或治疗方面的差异有关的范例(目标3)； 评估资助项目的进展，并促进其演变为全孢子项目或独立项目 资助项目(目标4)。为了实现这些目标，DRP每年将奖励10万美元，以资助至少一个 每年都有前景看好的项目。如果获奖者满意，将有资格再获得一年的续期资助 取得了进展，并提出了可接受的第二年提案和计划。招揽顾客的策略 DRP申请将包括直接向杜克癌症研究所、杜克大学医学院的所有教职员工征集 医学院和杜克大学。此外，全国其他机构的癌症差异研究项目 将被联系，并将在适当的临床和科学期刊上刊登广告，以吸引 杜克大学以外的协作应用程序。所有DRP应用程序都将经过透明的多层对等 审查流程。DRP获奖者将被要求轮流提交其项目的进展报告 在执行委员会每两周举行一次的会议上，他们将收到反馈。DRP及其流程 将作为DCHD P20孢子评估的一部分每年进行评估，并为下一次制定改进措施 征集、评审和奖励的循环。